Industry News

newsicon-industry

News from the global pharmaceuticals industry about head lice treatments and corporate developments, including takeovers and mergers.

05.06.14 | VaMousse now available online across the US

TyraTech Inc recently announced that their VaMOUSSE! range of head lice products are available to purchase online in the United States.

24.01.14 | Tyratech to sell Vamousse through Walmart

Tyratech have recently announced a deal to sell Vamousse, their preventative head lice treatment product, through Walmart in the US.

07.10.13 | Tyratech discussing US distribution of head lice products

Tyratech Inc. is in discussions with distributors to increase the exposure of its head lice treatment range to markets in the US.

06.06.13 | Eden Research Licence Agreement

Eden Research has announced an agreement with Neo-Pharma Innovations to develop their terpene-based head lice treatment for commercial sale.

14.12.12 | New funding and efficacy data for Hatchtech

Hatchtech, Pty Ltd have announced the completion of their financing round and published new data on the active ingredient in their DeOvo pediculicide product.

13.12.12 | TyraTech receives Product Registration in UK

TyraTech, Inc, has received notification from the UK regualtory body that their VaMOUSSE!™ head lice product has been registered as a medical device.

13.09.12 | Successful End-Of-Phase-2 consultations for DeOvo

The anti-lice product DeOvo, developed by Hatchtech Pty Ltd, has successfully completed its end-of-phase II consultations with the FDA.

24.08.12 | Sklice now available by prescription in the US

Sanofi Pasteur announced this week that Sklice, their ivermectin-based head lice treatment is now commercially available by prescription in the US.

27.07.12 | DeOvo granted patent by US PTO

The active ingredient in the DeOvo head lice treatment, produced by Hatchtech Pty Ltd, has been granted a patent by the US Patent and Trademark Office.

09.05.12 | Hatchtech finances Phase III DeOvo trials

The Australian speciality pharma company Hatchtech Pty Ltd has recently announced a new round of funding to support ongoing DeOvo trials, as well as a new CEO.

Site Map   |    Privacy Policy   |   Terms & Conditions

© 2012-2013 pediculosis.com — all rights reserved